Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators believe that iloprost will improve gas exchange in COPD patients with pulmonary hypertension.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• FEV1 < 65% of predicted and FEV1 to FVC ratio < 70%

• Baseline PAO2 while stable between 60-75 mmHg and

• The ability to provide informed consent

Exclusion Criteria:

• Clinical instability as evidenced by an acute exacerbation requiring an intensification of therapy and/or the need for hospitalization with the preceding 3 months.

• Presence of an additional cause of lung disease as suggested by history, clinical or radiographic findings, or pulmonary function tests

• Presence of left ventricular dysfunction and/or left atrial enlargement by echo, ECHO or catheterization

• Heparin allergy

• Pregnancy or breast feeding